Price To Earnings Ratio 72.01 | Sector PE 69.55 |
PB Ratio 6.22 | Sector PB 8.96 |
EPS 21.57 | Dividend Yield 0.32 |
Today's Volume 688.385 K | 5 Day Avg. Volume 1.531 M |
PEG Ratio 4.46 | Market Cap. ₹ 38,920.00 Cr. |
Ipca Laboratories Limited is an Indian pharmaceutical company. The company manufactures and markets more than 350 dosage forms and approximately 80 active ingredients (APIs) covering various therapeutic segments. It offers APIs such as atenolol, chloroquine phosphate, chlorthalidone, furosemide, hydroxychloroquine sulfate, losartan, metoprolol succinate, metoprolol tartrate, pyrantel salts and propranolol. The company offers brands such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The company's products are sold in more than 100 countries around the world. The company has 18 manufacturing facilities in India that manufacture APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.